Logo image
Back
Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009
Journal article   Open access   Peer reviewed

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009

Wilbur H Chen, Patricia L Winokur, Kathryn M Edwards, Lisa A Jackson, Anna Wald, Emmanuel B Walter, Diana L Noah, Mark Wolff, Karen L Kotloff and Pandemic H1N1 Vaccine Adult Study Group
Vaccine, Vol.30(28), pp.4240-4248
06/13/2012
DOI: 10.1016/j.vaccine.2012.04.044
PMCID: PMC3490194
PMID: 22537984
url
https://doi.org/10.1016/j.vaccine.2012.04.044View
Published (Version of record) Open Access

Abstract

► Two independent randomized, double-blind, multi-center clinical trials were performed. ► Preliminary results generated within 6months after the pandemic emerged were used to inform public health recommendations. ► Both vaccines appeared safe and well-tolerated and elicited a robust HI antibody response after a single 15μg dose. ► The more modest responses seen among elderly subjects could potentially be improved with the use of a higher vaccine dosage. The influenza A/H1N1 pandemic in 2009 created an urgent need to develop vaccines for mass immunization. To guide decisions regarding the optimal immunization dosage and schedule for adults, we evaluated two monovalent, inactivated, unadjuvanted H1N1 influenza vaccines in independent, but simultaneously conducted, multi-center Phase 2 trials of identical design. Healthy adults, stratified by age (18–64years and ≥65years), were randomized (1:1 allocation), in a double-blind, parallel-group design, to receive two intramuscular doses (21days apart) of vaccine containing approximately 15μg or 30μg of hemagglutinin (HA). Primary endpoints were safety (reactogenicity for 8days after each vaccination and vaccine-associated serious adverse events during the 7month study) and immunogenicity (proportion of subjects, stratified by age, achieving a serum hemagglutination inhibition [HI] antibody titer ≥1:40 or a ≥4-fold rise in titer after a single injection of either dosage). Both vaccines were well-tolerated. A single 15μg dose induced HI titers ≥1:40 in 90% of younger adults (95% confidence interval [CI] 82–95%) and 81% of elderly (95% CI 71–88%) who received Sanofi-Pasteur vaccine (subsequently found to contain 24μg HA in the standard potency assay), and in 80% of younger adults (95% CI 71–88%) and 60% of elderly (95% CI 50–70%) who received CSL vaccine. Both vaccines were significantly more immunogenic in younger compared with elderly adults by at least one endpoint measure. Increasing the dose to 30μg raised the frequency of HI titers ≥1:40 in the elderly by approximately 10%. Higher dosage did not significantly enhance immunogenicity in younger adults and a second dose provided little additional benefit to either age group. These trials provided evidence for policymakers that a single 15μg dose of 2009 A/H1N1 vaccine would likely protect most U.S. adults and suggest a potential benefit of a 30μg dose for the elderly.
 Influenza Vaccines Pandemic

Details

Metrics

9 Record Views
21 Times Cited - Web of Science
Logo image